How Journals and Sponsors Shape Open Access in Clinical Trial Publication

Introduction: Why Open Access is Now Non-Negotiable

Open access (OA) has moved from being an academic preference to a clinical trial mandate. Regulatory agencies, funding bodies, and public advocacy groups are demanding increased transparency and wider availability of trial data. At the center of this movement are journal publishers and study sponsors, whose open access policies shape how, when, and where clinical trial results are published and accessed.

This article dives into the policies enforced by top medical journals and sponsors, the legal and ethical mandates around data dissemination, and the strategic decisions pharma professionals must make to stay compliant with evolving expectations.

Types of Open Access Models Explained

Before exploring specific policies, it’s crucial to understand the main OA models that journals and sponsors support:

• Gold Open Access: Articles are immediately free upon publication. Often involves an Article Processing Charge (APC).
• Green Open Access: Authors self-archive a version (pre-print or post-print) in a public repository after an embargo period.
• Hybrid Access: Subscription journals offer optional open access for individual articles upon payment of APC.
• Bronze Access: Articles are free to read but lack a clear reuse license.

Most clinical trial sponsors favor Gold or Green models to ensure compliance with funder mandates and transparency guidelines.

Major Sponsor Requirements for Open Access

Pharmaceutical sponsors and public agencies have begun enforcing open access publication as a formal requirement. Below is a snapshot of leading mandates:

Open Access Mandates from Major Journals

Leading medical journals have differing OA policies that authors must navigate:

• The BMJ: Full Gold OA journal. Mandates CC-BY license for research articles.
• NEJM: Subscription-based with optional OA for selected articles (high APC).
• The Lancet: Hybrid model. OA allowed with Plan S-aligned license and payment.
• JAMA: Permits Green OA after embargo. Offers OA for funder-mandated papers.
• PLOS ONE: Gold OA journal. No subscription content. APC applies to all.

Authors publishing trial results must align journal selection with sponsor obligations and transparency goals.

Plan S and the Rise of Funder-Led Publishing Requirements

Plan S is a coalition of funders including the European Commission, Wellcome Trust, and others requiring that all research they fund be published in compliant OA journals or platforms. Requirements include:

• Immediate open access without embargo
• Use of Creative Commons Attribution License (CC BY)
• Deposition in approved repositories
• Transparency in APC pricing

For clinical trial teams working under these funders, failing to publish in a compliant venue may jeopardize future funding.

Case Example: NIH-Funded Oncology Trial

A multicenter oncology trial funded by the NIH completed in 2022. As per NIH’s Public Access Policy, the manuscript was submitted to a hybrid journal that did not offer immediate open access. The team faced the following challenges:

• Delayed deposit of the accepted manuscript in PubMed Central
• Need to revise the publishing agreement to enable Green OA
• Inclusion of proper grant acknowledgment and NIH grant number

Ultimately, compliance was achieved after coordination with the publisher and NIH Manuscript Submission system (NIHMS).

Embargo Periods: How Long Can Access Be Delayed?

Embargoes refer to the time between article publication and when it becomes freely accessible in a public repository. Funders and journals vary:

• NIH: 12 months maximum
• Wellcome: No embargo allowed
• EC Horizon: Immediate access required
• NEJM: 6 months common unless OA option selected

Trial sponsors must integrate embargo planning into their publication strategy to avoid non-compliance.

Journals vs Repositories: Parallel Dissemination Strategy

Most funders allow dual routes of dissemination:

1. Journal Publication: Peer-reviewed, formal publication
2. Repository Submission: Depositing accepted manuscript in platforms like PubMed Central, Europe PMC, or institutional repositories

For example, a trial published in JAMA may have its accepted version archived in Europe PMC under funder guidelines. Both routes contribute to visibility and access.

Publication SOPs for Sponsors

Pharma companies and CROs must maintain internal SOPs that align with global OA mandates. These SOPs often include:

• Pre-submission compliance checks
• Preferred journal list with OA compatibility
• Coordination with medical writers and authors
• Archiving requirements in corporate repositories
• Communication with funders on embargo negotiations

Failure to follow these SOPs can result in inspection findings under GPP3 (Good Publication Practice) guidelines.

Best Practices for Trial Teams

• Check funder OA mandates before selecting a journal
• Choose journals indexed in trial registries or connected to ORCID/iCite
• Budget for APCs in grant or sponsor funding plans
• Document all communications with publishers regarding access rights
• Use institutional OA advisors to resolve legal conflicts

Planning ahead minimizes the risk of non-compliance and improves the trial’s dissemination timeline.

Conclusion: Ensuring Access to Scientific Knowledge

Open access policies are no longer optional — they are legally and ethically mandated across the global clinical trial landscape. Journals and sponsors play pivotal roles in ensuring trial outcomes are not locked behind paywalls. By understanding the varying models, planning for APCs, and aligning with sponsor and funder expectations, clinical research teams can ensure that trial results reach the widest possible audience — fostering public trust, advancing science, and meeting transparency goals.

Crafting Effective Summary Results Tables for Clinical Trial Registries

Importance of Summary Tables in Results Disclosure

Summary results tables are the foundation of data transparency on public clinical trial registries. These tables condense the trial’s key findings into structured, readable, and regulatory-compliant formats. Agencies like the FDA, EMA, and WHO require accurate tabular summaries for participant flow, baseline characteristics, outcomes, and adverse events.

Whether you are posting on ClinicalTrials.gov, EudraCT, or CTIS, proper table design ensures reviewers, patients, and regulators can interpret the study outcomes clearly. Poorly formatted or incomplete tables are a leading cause of Quality Control (QC) errors and result rejections.

Essential Table Types and What They Should Include

The four primary table categories common to most registries include:

• Participant Flow: Number of participants assigned, completed, or withdrawn at each phase.
• Baseline Characteristics: Demographic and clinical profile of the randomized population.
• Outcome Measures: Primary and secondary endpoint data with effect sizes and confidence intervals.
• Adverse Events: Summary of all reported adverse events, serious and non-serious, by arm.

Each table must be populated based on the analysis population defined in the statistical analysis plan (e.g., ITT or PP). The granularity required depends on the registry. CTIS and EudraCT support broader formats, while ClinicalTrials.gov enforces stricter structural and numerical rules through its PRS (Protocol Registration and Results System).

How to Structure a Baseline Characteristics Table

The baseline table helps readers determine whether the treatment groups were balanced before intervention. It must include:

• Age (mean ± SD or median + range)
• Sex (M/F counts and %)
• Disease duration or severity scale, if relevant
• Any other trial-specific covariates

Sample format:

Ensure that the totals match the number randomized in the participant flow table, as mismatches often trigger registry errors or flags.

Creating Effective Outcome Measure Tables

Outcome tables must show both statistical and clinical relevance. They typically include:

• Outcome label (e.g., “Change in Systolic Blood Pressure at Week 12”)
• Time point (Day, Week, Month)
• Value per group (Mean ± SD or Median + IQR)
• Between-group difference (if applicable)
• 95% Confidence Interval (CI)
• p-value (only if required by registry or protocol)

Tip: If results are unavailable at the time of posting, use “NA” but explain the reason in the free-text comment field of the registry.

Adverse Event Summary Table Formatting

Registries often require both all-cause and serious adverse event summaries. Adverse Event (AE) tables should follow standard MedDRA hierarchy or investigator terms. Include:

• Total number of participants experiencing ≥1 AE
• System organ class / Preferred term
• Severity (Mild, Moderate, Severe)
• Serious vs Non-serious status

Example Table:

Ensure AE totals reflect the safety population and align with source documents submitted to health authorities or used in the CSR.

Tools and Templates for Creating Tables

Several sponsors use predefined Excel templates to collate registry-compliant summary data. Tools such as:

• ClinicalTrials.gov PRS XML validator
• CTIS Module 5 format guidelines
• EudraCT Results QC checklist

can reduce formatting errors. Templates should include field-level instructions (e.g., decimal places, mandatory fields, allowable ranges) and be shared with all relevant stakeholders (Biostats, MW, QA).

For reusable templates, visit PharmaSOP.in.

Common Quality Control Failures and Fixes

Registry submissions often get flagged due to:

• Inconsistent participant numbers across tables
• Invalid statistical formats (e.g., CI without limits)
• Missing timepoints in outcome tables
• AE percentages exceeding 100%
• Unexplained “NA” entries

Before submission, perform a peer QC or use internal registry compliance tools. Annotated table maps that link to SAP and source data files are highly recommended.

Conclusion

Well-crafted summary tables not only fulfill a regulatory mandate but also build public and scientific trust. Consistency, traceability, and format accuracy are key to successful results posting. Training medical writers and data managers in these practices helps reduce delays and regulatory queries.

Explore more guidance on registry data formatting and transparency expectations at ICH.org.

Ensuring Transparency in Rare Disease Clinical Trial Reporting

Why Transparency Matters in Rare Disease Trials

In rare disease research, every datapoint matters. Due to the small patient populations, heterogeneous outcomes, and complex endpoints, publishing accurate and timely trial results becomes not just a regulatory requirement but a moral imperative. Transparency in clinical trial reporting ensures that patients, caregivers, regulators, and the scientific community have access to essential data that can shape future research, guide treatment decisions, and promote trust in clinical science.

Failure to disclose negative, inconclusive, or delayed outcomes not only skews the scientific literature but also disrespects the contributions of participants and may misguide clinical decisions. This is especially critical in rare diseases, where anecdotal evidence may drive decisions in the absence of comprehensive data.

Transparent reporting in rare disease trials supports regulatory decisions, funding prioritization, and development of clinical practice guidelines—while honoring the efforts of those who participate in research hoping to help themselves and others.

Regulatory Requirements for Trial Reporting

Various global regulatory bodies have established mandatory guidelines for clinical trial registration and results disclosure:

• FDAAA 801: In the U.S., applicable clinical trials must post results on ClinicalTrials.gov within 12 months of completion.
• EU Clinical Trials Regulation (CTR): Requires summary results to be posted on the EU Clinical Trials Register within 12 months, or 6 months for pediatric studies.
• WHO Joint Statement: Endorses universal registration and public disclosure of results, including negative findings, to prevent selective reporting.

These regulations cover both commercial and investigator-initiated studies and apply across all therapeutic areas—including rare and orphan diseases. Non-compliance can lead to monetary penalties, public disclosure of noncompliance, or even suspension of future trial approvals.

Common Challenges in Reporting Rare Disease Trials

Despite best intentions, rare disease trials often encounter unique obstacles that hinder transparent outcome dissemination:

• Small sample sizes: Difficulties in recruitment or early trial termination may yield underpowered data, making sponsors reluctant to publish results.
• Unconventional endpoints: Novel biomarkers or patient-reported outcomes may lack standardized reporting frameworks.
• Data protection concerns: In ultra-rare conditions, individual patient data may be potentially identifiable, posing privacy risks.
• Sponsorship complexity: Multi-sponsor collaborations or public-private partnerships may delay consensus on data ownership and publication rights.

Addressing these barriers requires planning, resource allocation, and commitment to transparency from protocol inception through trial closure.

Strategies for Ethical and Timely Disclosure

To promote compliance and ethical conduct, sponsors and investigators can adopt the following strategies:

1. Integrate Reporting into Trial Planning

• Include a data sharing and results disclosure plan in the protocol and informed consent documents
• Budget time and resources for post-study analysis, lay summaries, and registry uploads

2. Use Lay Summaries and Plain Language

• Prepare patient-friendly summaries explaining key outcomes, side effects, and next steps
• Translate into multiple languages to reflect global enrollment demographics

3. Collaborate with Advocacy Groups

• Engage rare disease organizations to co-disseminate results to the broader patient community
• Use newsletters, webinars, or social media to share study progress and publications

4. Utilize Open Access Platforms

• Publish findings in open-access journals or preprint repositories
• Ensure trial data and interpretations are available to independent researchers and clinicians

Case Example: Transparent Reporting in a Lysosomal Storage Disorder Trial

In a Phase II trial for Niemann-Pick Type C disease, early endpoints failed to demonstrate statistical significance. Instead of suppressing the data, the sponsor published results in an open-access journal and hosted a public webinar with researchers and patient advocacy leaders.

This approach resulted in:

• Enhanced scientific discourse on endpoint selection and trial design
• Increased trust among trial participants and families
• Informing subsequent protocol amendments in future studies

The trial became a model of transparency in the rare disease community and strengthened collaborative networks across research and patient communities.

Global Registries and Data-Sharing Mandates

Beyond national registries, rare disease studies can benefit from inclusion in global trial platforms such as:

• EU Clinical Trials Register
• Be Part of Research (UK)
• Japan’s RCT Portal

These registries improve trial visibility, enable cross-study comparisons, and enhance public accountability. When harmonized across agencies, they can also reduce duplication and stimulate cross-border research in ultra-rare conditions.

Ethical Imperatives and Future Trends

Transparent reporting in rare disease trials is not just about ticking regulatory boxes. It reflects the core values of clinical research: integrity, respect, and societal contribution. Emerging trends are reinforcing these principles:

• Patient co-authorship: Some journals now encourage inclusion of patients as co-authors in trial publications.
• Blockchain and secure platforms: Tools are emerging to track data transparency and reporting compliance in real time.
• AI-driven analysis: Artificial intelligence is being used to detect underreporting or identify unpublished trials across databases.

Regulators, sponsors, and the public alike are demanding higher levels of accountability and real-world impact. Rare disease trials, due to their inherently high stakes, must lead by example.

Conclusion: Making Transparency the Norm, Not the Exception

In rare disease research, the ethical stakes are high. Transparent reporting ensures that knowledge gained from a few precious cases is not lost. It allows future therapies to be built on solid ground and ensures that the voices of patients and families are heard long after the trial ends.

By embedding transparency into every phase—from protocol to publication—rare disease sponsors can uphold public trust, meet regulatory obligations, and accelerate progress for some of the most vulnerable patient populations in medicine today.